Beryl Drugs Limited
BERLDRG.BO
Get informed when a big investor buys or sells
+ FollowMarket Cap$133.44M
Close$
$-25.32
200.1% downside
Current Fair Value
200.1% downsideOvervalued by 200.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $133.44 Million |
|---|---|
| Enterprise Value | $155.11 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.84 |
| Beta | -0.02 |
| Outstanding Shares | 5,071,700 |
Return
| Return on Equity | 6.32% |
|---|---|
| Return on Assets | 4.17% |
| Return on Invested Capital | 10.43% |
Valuation & Multiples
| P/E Ratio | 21.22 |
|---|---|
| PEG | 2.24 |
| Price to Sales | 0.59 |
| Price to Book Ratio | 1.33 |
| Enterprise Value to Revenue | 0.7 |
| Enterprise Value to EBIT | 14.19 |
| Enterprise Value to Net Income | 24 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Beryl Drugs Limited
22 employees
CEO: Sanjay Sethi Beryl Drugs Limited focuses on the manufacturing of bulk pharmaceutical ingredients. Its comprehensive product portfolio encompasses liquid and dry small-volume injectable medications, ophthalmic and otic solutions, intravenous (IV) flui...